Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
Frontiers in immunology
; 12, 2021.
Article
in English
| EuropePMC | ID: covidwho-1678789
ABSTRACT
CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Type of study:
Experimental Studies
Topics:
Vaccines
Language:
English
Journal:
Frontiers in immunology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS